---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-179958"
form_type: "8-K"
ticker: "CMPX"
cik: "0001738021"
company_name: "Compass Therapeutics, Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T13:57:46.142617+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Compass Therapeutics prices $120M upsized public offering of common stock and pre-funded warrants

## Summary
- Priced upsized $120M offering: 33.29M shares at $3.00/share and 6.71M pre-funded warrants at $2.9999 each.
- Net proceeds estimated at $112.5M (base), up to $129.5M if underwriters' 30-day option for 6M additional shares is exercised.
- Proceeds to fund commercial readiness, R&D of product candidates, and general corporate purposes.
- Cash and equivalents expected to fund operations into 2028.
- Jefferies, Piper Sandler, and Guggenheim Securities are joint bookrunners.

## SEC filing metadata
- accession: 0001193125-25-179958
- form_type: 8-K
- ticker: CMPX
- cik: 0001738021
- company_name: Compass Therapeutics, Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1738021/000119312525179958/0001193125-25-179958-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1738021/000119312525179958/d153873d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-179958
- JSON: https://secwatch.observer/filing/0001193125-25-179958.json
- Plain text: https://secwatch.observer/filing/0001193125-25-179958.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.